RT Journal Article
SR Electronic
T1 Identification of Somatic Structural Variants in Solid Tumors By Optical Genome Mapping
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.04.21250683
DO 10.1101/2021.02.04.21250683
A1 David Y. Goldrich
A1 Brandon LaBarge
A1 Scott Chartrand
A1 Lijun Zhang
A1 Henry B. Sadowski
A1 Yang Zhang
A1 Khoa Pham
A1 Hannah Way
A1 Chi-Yu Jill Lai
A1 Andy Wing Chun Pang
A1 Benjamin Clifford
A1 Alex R. Hastie
A1 Mark Oldakowski
A1 David Goldenberg
A1 James R. Broach
YR 2021
UL http://medrxiv.org/content/early/2021/02/09/2021.02.04.21250683.abstract
AB Genomic structural variants comprise a significant fraction of somatic mutations driving cancer onset and progression. However, such variants are not readily revealed by standard next generation sequencing. Optical genome mapping (OGM) surpasses short read sequencing in detecting large (>500bp) and complex structural variants (SVs) but requires isolation of ultra-high molecular weight DNA from the tissue of interest. We have successfully applied a protocol involving a paramagnetic nanobind disc to a wide range of solid tumors. Using as little as 6.5mg of input tumor tissue, we show successful extraction of high molecular weight genomic DNA that provides a high genomic map rate and effective coverage by optical mapping. We demonstrate the system’s utility at identifying somatic SVs affecting functional and cancer-related genes for each sample. Duplicate/triplicate analysis of select samples shows intra-sample reliability but also intra-sample heterogeneity. We also demonstrate that simply filtering SVs based on a GRCh38 human control database provides high positive and negative predictive values for true somatic variants. Our results indicate that the solid tissue DNA extraction protocol, OGM and SV analysis can be applied to a wide variety of solid tumors to capture SVs across the entire genome with functional importance in cancer prognosis and treatment.Competing Interest StatementHB Sadowski, Y Zhang, K Pham, H Way, CYJ Lai, AWC Pang, B Clifford, AR Hastie and M Oldakowski are employees of BionanoGenomicsFunding StatementThis study was supported in part by a grant from the George Laverty Foundation (DG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Acquisition of tumors samples were performed under IRB Protocol 40532 from the Penn State Health Institution Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request from James R. Broach (jbroach@hmc.psu.edu)